NCCN Allocates $X Million to Boost Lung Cancer Screening Adherence
Event summary
- NCCN Oncology Research Program awarded grants to four projects aimed at improving lung cancer screening rates.
- Funding provided by Merck will support initiatives to reduce disparities and barriers in screening adherence.
- Projects include social network-based interventions, imaging optimization, and community-clinic collaboration.
- Selected projects will be completed within two years, with peer-reviewed proposals from NCCN Member Institutions.
The big picture
Lung cancer remains the leading cause of cancer deaths in the U.S., with over 225,000 new diagnoses estimated in 2025. Despite the proven efficacy of screening in early detection, adherence to guidelines lags significantly. NCCN's strategic investment in these quality improvement projects underscores the critical need to enhance screening uptake, particularly among underserved populations. The initiative aligns with broader industry efforts to leverage data-driven interventions for improving cancer care outcomes.
What we're watching
- Program Efficacy
- Whether the funded projects can demonstrate measurable improvements in screening rates and patient outcomes within the two-year timeline.
- Disparity Reduction
- The extent to which these initiatives can minimize disparities in lung cancer screening access across different populations.
- Scalability
- The pace at which successful interventions can be scaled beyond the initial pilot projects to broader populations.
Related topics